Hydrocephalus, also known as “water on the brain”, is a condition in which excess cerebrospinal fluid accumulates in the brain, leading to an enlargement of the ventricles. This accumulation of fluid can cause a wide range of neurological symptoms, including headaches, difficulty walking, and cognitive impairment. In severe cases, hydrocephalus can lead to blindness, coma, and even death. For many years, the primary treatment for hydrocephalus has been the surgical insertion of a shunt. This device is used to divert the excess fluid away from the brain and into another area of the body where it can be absorbed. While this treatment has been successful in many cases, it can also be associated with a number of risks and complications, including infection, blockage, and malfunction. In recent years, however, medical professionals have been exploring new treatment options for hydrocephalus that offer a more effective and less invasive alternative to traditional shunt surgery. In this article, we will explore these new treatments and discuss the potential benefits they offer for those living with hydrocephalus.
Endoscopic Third Ventriculostomy (ETV) is a minimally invasive procedure that is used to treat hydrocephalus. During the procedure, a small hole is created in the floor of the third ventricle, allowing the excess fluid to drain out of the brain and be absorbed into the body. This procedure has been found to be effective in treating hydrocephalus in some cases, and is associated with fewer risks and complications than traditional shunt surgery. One of the primary benefits of ETV is that it allows the patient to avoid the risks associated with shunt surgery, such as infection, blockage, and malfunction. Additionally, ETV can be performed in a shorter amount of time than shunt surgery, and the patient can typically return home the same day.
Stereotactic Ventriculocisternostomy (SV) is a newer procedure that is similar to ETV, but is performed using a special imaging technique known as stereotactic navigation. During the procedure, a small hole is created in the floor of the third ventricle, allowing the excess fluid to drain out of the brain and be absorbed into the body. Similar to ETV, SV is associated with fewer risks and complications than traditional shunt surgery. Additionally, it is less invasive and can be performed in a shorter amount of time than shunt surgery.
Ventriculoperitoneal shunting (VPS) is a procedure in which a tube is surgically inserted into the brain to drain excess fluid into the abdomen. This procedure is typically used in cases where ETV and SV are not appropriate or have failed. While VPS is associated with a number of risks and complications, it can be effective in treating hydrocephalus in some cases.
Hydrocephalus is a serious condition that can cause a wide range of neurological symptoms. For many years, the primary treatment for hydrocephalus has been the surgical insertion of a shunt. However, medical professionals have been exploring new treatment options for hydrocephalus that offer a more effective and less invasive alternative to traditional shunt surgery. Endoscopic Third Ventriculostomy (ETV), Stereotactic Ventriculocisternostomy (SV), and Ventriculoperitoneal Shunting (VPS) are three of the most commonly used treatments for hydrocephalus. Each of these procedures has its own set of risks and benefits, and it is important to discuss these with your doctor before deciding which treatment is right for you. With the right treatment, those living with hydrocephalus can experience an improved quality of life.
1.
Pancreatic cancer patients who were prescribed lorazepam for anxiety had poorer survival rates.
2.
Upping Immunotherapy Activity; A Win for Lung Screening; Looming Drug Price Break?
3.
New First-Line Option for Advanced ALK-Positive Lung Cancer
4.
Research indicates that extended PSMA therapy is safe and effective for patients with prostate cancer.
5.
Researchers identify potential new therapeutic targets for treating T-cell lymphoma and natural killer cell tumors.
1.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
2.
Cancer Stem Cells: The Seeds of Tumorigenesis and Recurrence
3.
Unlocking the Potential of Glofitamab: A Novel Treatment for Cancer
4.
Managing High Potassium Levels: A Comprehensive Guide to Veltassa
5.
All About Ferric Gluconate – The Best Source Of Iron For Anemia
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
2.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
3.
Navigating the Complexities of Ph Negative ALL - Part XII
4.
The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.
5.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation